Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection

Abstract Background Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and cl...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of infectious diseases Ročník 221; číslo 10; s. 1677 - 1687
Hlavní autoři:	Miao, Zhijiang, Zhang, Shaoshi, Ou, Xumin, Li, Shan, Ma, Zhongren, Wang, Wenshi, Peppelenbosch, Maikel P, Liu, Jiaye, Pan, Qiuwei
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	US Oxford University Press 27.04.2020
Témata:	Developing Countries Global Health Hepatitis D - epidemiology Hepatitis D - pathology Hepatitis D - virology Hepatitis Delta Virus Humans Prevalence Risk Factors epidemiology disease progression cirrhosis hepatitis delta virus hepatocellular carcinoma
ISSN:	0022-1899, 1537-6613, 1537-6613
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Abstract Background Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection. Methods We conducted a meta-analysis with a random-effects model and performed data synthesis. Results The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63–1.00) among the general population and 13.02% (95% CI, 11.96–14.11) among HBV carriers, corresponding to 48–60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84–34.29), 25.77% (95% CI, 20.62–31.27), and 19.80% (95% CI, 10.97–30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65–5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79–8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average. Conclusions Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment. Forty-eight to 60 million individuals are infected with HDV around the globe, and Asia and Africa are the worst-hit areas. HDV infection predisposes to rapid progression into severe liver diseases, particularly liver cirrhosis.
AbstractList	Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection.BACKGROUNDHepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection.We conducted a meta-analysis with a random-effects model and performed data synthesis.METHODSWe conducted a meta-analysis with a random-effects model and performed data synthesis.The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63-1.00) among the general population and 13.02% (95% CI, 11.96-14.11) among HBV carriers, corresponding to 48-60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84-34.29), 25.77% (95% CI, 20.62-31.27), and 19.80% (95% CI, 10.97-30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65-5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79-8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average.RESULTSThe pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63-1.00) among the general population and 13.02% (95% CI, 11.96-14.11) among HBV carriers, corresponding to 48-60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84-34.29), 25.77% (95% CI, 20.62-31.27), and 19.80% (95% CI, 10.97-30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65-5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79-8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average.Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment.CONCLUSIONSFindings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment. Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection. We conducted a meta-analysis with a random-effects model and performed data synthesis. The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63-1.00) among the general population and 13.02% (95% CI, 11.96-14.11) among HBV carriers, corresponding to 48-60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84-34.29), 25.77% (95% CI, 20.62-31.27), and 19.80% (95% CI, 10.97-30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65-5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79-8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average. Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment. Abstract Background Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection. Methods We conducted a meta-analysis with a random-effects model and performed data synthesis. Results The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63–1.00) among the general population and 13.02% (95% CI, 11.96–14.11) among HBV carriers, corresponding to 48–60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84–34.29), 25.77% (95% CI, 20.62–31.27), and 19.80% (95% CI, 10.97–30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65–5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79–8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average. Conclusions Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment. Forty-eight to 60 million individuals are infected with HDV around the globe, and Asia and Africa are the worst-hit areas. HDV infection predisposes to rapid progression into severe liver diseases, particularly liver cirrhosis.
Author	Miao, Zhijiang Peppelenbosch, Maikel P Zhang, Shaoshi Li, Shan Ma, Zhongren Ou, Xumin Wang, Wenshi Pan, Qiuwei Liu, Jiaye
Author_xml	– sequence: 1 givenname: Zhijiang surname: Miao fullname: Miao, Zhijiang organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 2 givenname: Shaoshi surname: Zhang fullname: Zhang, Shaoshi organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 3 givenname: Xumin surname: Ou fullname: Ou, Xumin organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 4 givenname: Shan surname: Li fullname: Li, Shan organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 5 givenname: Zhongren surname: Ma fullname: Ma, Zhongren organization: Biomedical Research Center, Northwest Minzu University, Lanzhou, People’s Republic of China – sequence: 6 givenname: Wenshi surname: Wang fullname: Wang, Wenshi organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 7 givenname: Maikel P surname: Peppelenbosch fullname: Peppelenbosch, Maikel P organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 8 givenname: Jiaye surname: Liu fullname: Liu, Jiaye email: q.pan@erasmusmc.nl organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands – sequence: 9 givenname: Qiuwei surname: Pan fullname: Pan, Qiuwei email: q.pan@erasmusmc.nl organization: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31778167$$D View this record in MEDLINE/PubMed
BookMark	eNpFkD1PwzAURS0EgrYwsiKPDAT87MRORtRCQapUBmCNHOelGCV2iR0k-PUElY_pSe-ee4czJfvOOyTkFNglsEJcWdfUNly92k8pxB6ZQCZUIiWIfTJhjPME8qI4ItMQXhljqZDqkBwJUCoHqSbE3YRoOx2t29D4gnTZ-kq39KHHd92iM3hBFzagDjj-_KbHEKx3F1S7ms5b66wZ6fUQje-Q-obe4XYcizbQBbZR02fbD4HeuwZNHIvH5KDRbcCTnzsjT7c3j_O7ZLVe3s-vV4nJII2JknneIHJZKQ68SvMm45inBSiemTHUDCBlQubKcABgCIU2DDOos6JKFRczcr7b3fb-bcAQy84Gg22rHfohlFxAkRacKzmiZz_oUHVYl9t-9NF_lL-O_rf8sP1LgZXf-sud_nKnX3wBi5J4cQ
CitedBy_id	crossref_primary_10_1016_S2468_1253_23_00279_0 crossref_primary_10_1016_j_jhep_2020_11_032 crossref_primary_10_4254_wjh_v16_i4_640 crossref_primary_10_17235_reed_2025_11393_2025 crossref_primary_10_1111_jvh_13939 crossref_primary_10_3390_livers5020023 crossref_primary_10_3390_v15122345 crossref_primary_10_1097_CLD_0000000000000113 crossref_primary_10_1097_CM9_0000000000002011 crossref_primary_10_1111_jvh_13811 crossref_primary_10_1080_22221751_2023_2276337 crossref_primary_10_1080_14712598_2024_2313112 crossref_primary_10_3390_jcm11113093 crossref_primary_10_3390_v17081100 crossref_primary_10_3390_v13081532 crossref_primary_10_1016_j_gastha_2023_06_014 crossref_primary_10_1016_j_cgh_2023_04_022 crossref_primary_10_3748_wjg_v27_i24_3530 crossref_primary_10_1007_s41669_023_00466_3 crossref_primary_10_3390_v13040555 crossref_primary_10_1111_liv_14833 crossref_primary_10_1111_liv_15921 crossref_primary_10_1038_s41598_021_87975_5 crossref_primary_10_3748_wjg_v26_i38_5759 crossref_primary_10_1136_gutjnl_2020_323888 crossref_primary_10_1093_jalm_jfaf092 crossref_primary_10_1016_j_psj_2022_102042 crossref_primary_10_1016_j_heliyon_2024_e31065 crossref_primary_10_3390_v13101912 crossref_primary_10_1002_ueg2_12564 crossref_primary_10_1111_jvh_70046 crossref_primary_10_1007_s11894_023_00901_9 crossref_primary_10_1016_j_jiph_2023_08_011 crossref_primary_10_3389_fmolb_2025_1598784 crossref_primary_10_3390_jpm12101580 crossref_primary_10_1111_liv_15338 crossref_primary_10_1111_liv_15579 crossref_primary_10_1055_a_2133_8614 crossref_primary_10_1136_gutjnl_2022_327216 crossref_primary_10_1016_j_jhep_2024_11_051 crossref_primary_10_3390_pathogens13050362 crossref_primary_10_1111_jvh_14005 crossref_primary_10_3390_ijms22052623 crossref_primary_10_3390_v12060648 crossref_primary_10_36290_vnl_2023_104 crossref_primary_10_1111_jvh_70029 crossref_primary_10_1016_j_jhep_2021_01_014 crossref_primary_10_3390_cells11223531 crossref_primary_10_1111_hiv_13581 crossref_primary_10_5888_pcd17_200324 crossref_primary_10_1111_liv_15467 crossref_primary_10_1155_2022_9102565 crossref_primary_10_1080_20477724_2022_2047551 crossref_primary_10_1016_j_chaos_2025_116037 crossref_primary_10_1016_j_ijid_2023_12_014 crossref_primary_10_1177_2049936120965027 crossref_primary_10_3390_v17040568 crossref_primary_10_1055_a_2181_3046 crossref_primary_10_1097_HC9_0000000000000168 crossref_primary_10_1016_j_jhep_2024_05_001 crossref_primary_10_1055_a_2181_3345 crossref_primary_10_1159_000513685 crossref_primary_10_3390_v17091220 crossref_primary_10_1097_HEP_0000000000000331 crossref_primary_10_3390_microorganisms12112177 crossref_primary_10_3390_ijms232415973 crossref_primary_10_1016_j_jhep_2024_12_044 crossref_primary_10_1155_2024_6622276 crossref_primary_10_1111_jvh_13577 crossref_primary_10_1097_QAD_0000000000002940 crossref_primary_10_1016_j_jhep_2023_10_030 crossref_primary_10_1016_j_aohep_2023_101175 crossref_primary_10_1038_s41571_023_00825_3 crossref_primary_10_1016_j_jhep_2022_07_016 crossref_primary_10_1186_s13099_021_00462_0 crossref_primary_10_3390_v13050788 crossref_primary_10_1016_j_aohep_2022_100770 crossref_primary_10_1016_j_jhep_2023_10_043 crossref_primary_10_1016_j_cld_2022_08_001 crossref_primary_10_2147_JEP_S235550 crossref_primary_10_5812_hepatmon_143785 crossref_primary_10_1186_s13690_021_00693_2 crossref_primary_10_1016_j_seppur_2023_123349 crossref_primary_10_3390_jpm13060964 crossref_primary_10_1016_j_jhep_2023_03_017 crossref_primary_10_1016_j_ijregi_2024_100560 crossref_primary_10_1055_a_1498_2512 crossref_primary_10_1136_sextrans_2024_056364 crossref_primary_10_1016_j_cld_2023_05_011 crossref_primary_10_3390_v15081695 crossref_primary_10_1080_14728214_2023_2205639 crossref_primary_10_4274_vhd_galenos_2022_2021_8_1 crossref_primary_10_1007_s12094_021_02673_y crossref_primary_10_1016_j_jmii_2021_03_014 crossref_primary_10_12998_wjcc_v9_i19_4890 crossref_primary_10_1016_j_cgh_2024_08_008 crossref_primary_10_4254_wjh_v16_i3_300 crossref_primary_10_1007_s10620_020_06584_w crossref_primary_10_1002_ueg2_12494 crossref_primary_10_3389_fcimb_2024_1422299 crossref_primary_10_1016_j_cld_2023_05_007 crossref_primary_10_1001_jama_2023_23242 crossref_primary_10_1016_j_jhep_2024_06_031 crossref_primary_10_7759_cureus_85200 crossref_primary_10_1097_HEP_0000000000000687 crossref_primary_10_1016_S1473_3099_22_00412_1 crossref_primary_10_1093_infdis_jiz634 crossref_primary_10_3390_v17010052 crossref_primary_10_3390_livers4030028 crossref_primary_10_1007_s00726_025_03465_2 crossref_primary_10_1111_liv_15387 crossref_primary_10_1186_s13104_022_05976_7 crossref_primary_10_1016_j_cld_2021_06_011 crossref_primary_10_1111_hepr_13936 crossref_primary_10_1097_QAD_0000000000003024 crossref_primary_10_1080_14712598_2023_2273260 crossref_primary_10_1016_j_gastrohep_2025_502337 crossref_primary_10_1016_j_ijregi_2025_100732 crossref_primary_10_3390_math10203917 crossref_primary_10_1038_s41598_023_49819_2 crossref_primary_10_1038_s41598_025_91765_8 crossref_primary_10_1371_journal_pone_0324682 crossref_primary_10_1097_MEG_0000000000002857 crossref_primary_10_1111_liv_15638 crossref_primary_10_1111_liv_15515 crossref_primary_10_3390_v14020198 crossref_primary_10_3390_v12111334 crossref_primary_10_1111_jvh_13899 crossref_primary_10_1097_HC9_0000000000000078 crossref_primary_10_3389_fmicb_2024_1472826 crossref_primary_10_3390_microorganisms11122895 crossref_primary_10_1016_j_clinre_2021_101677 crossref_primary_10_3390_cancers16223723 crossref_primary_10_1001_jama_2022_8384 crossref_primary_10_1136_sextrans_2023_056098 crossref_primary_10_1111_apt_16945 crossref_primary_10_3390_v17050667 crossref_primary_10_1016_j_eimce_2024_09_006 crossref_primary_10_1080_03007995_2024_2318004 crossref_primary_10_3390_v15081687 crossref_primary_10_3390_diseases13060168 crossref_primary_10_1111_liv_15770 crossref_primary_10_3390_biomedicines13020280 crossref_primary_10_1111_apt_18446 crossref_primary_10_1038_s41598_024_77737_4 crossref_primary_10_3390_pathogens13090793 crossref_primary_10_1111_apt_70251 crossref_primary_10_3748_wjg_v27_i24_3466 crossref_primary_10_1016_j_jhep_2022_05_023 crossref_primary_10_3390_v16111723 crossref_primary_10_1111_liv_70033 crossref_primary_10_1186_s43162_021_00036_1 crossref_primary_10_1016_j_ejogrb_2020_11_052 crossref_primary_10_7759_cureus_43362 crossref_primary_10_3390_life13051115 crossref_primary_10_1111_jvh_13797 crossref_primary_10_1128_spectrum_03965_22 crossref_primary_10_1007_s11901_023_00606_7 crossref_primary_10_1016_j_advms_2025_07_003 crossref_primary_10_3390_v15010214 crossref_primary_10_7759_cureus_79307 crossref_primary_10_1016_j_jhep_2022_08_041 crossref_primary_10_1186_s12985_020_01355_5 crossref_primary_10_14309_ctg_0000000000000509 crossref_primary_10_1016_j_jhepr_2022_100461 crossref_primary_10_25298_2616_5546_2020_4_2_171_176 crossref_primary_10_1016_j_gastrohep_2024_502241 crossref_primary_10_3390_jcm9010222 crossref_primary_10_1097_HEP_0000000000000642 crossref_primary_10_1111_liv_70026 crossref_primary_10_3389_fpubh_2022_1099571 crossref_primary_10_3390_v15071509 crossref_primary_10_1016_j_coph_2021_03_008 crossref_primary_10_3389_fmed_2022_1069372 crossref_primary_10_2478_jtim_2024_0015 crossref_primary_10_3389_fphar_2023_1128547 crossref_primary_10_3390_microorganisms13010118 crossref_primary_10_1016_j_jhep_2023_05_001 crossref_primary_10_2196_37016 crossref_primary_10_1371_journal_pone_0307746 crossref_primary_10_3389_fimmu_2022_893512 crossref_primary_10_1007_s11901_024_00643_w crossref_primary_10_14309_ajg_0000000000002810 crossref_primary_10_1002_cld_1106 crossref_primary_10_3389_fmicb_2022_992817 crossref_primary_10_1111_liv_15795 crossref_primary_10_1016_j_gastre_2025_502241 crossref_primary_10_3748_wjg_v28_i1_76 crossref_primary_10_3390_v13050830 crossref_primary_10_3390_pathogens10101227 crossref_primary_10_1128_jvi_01280_25 crossref_primary_10_1016_j_jhep_2020_02_030 crossref_primary_10_3390_antiox12040974 crossref_primary_10_5812_hepatmon_101630 crossref_primary_10_1097_TP_0000000000004138 crossref_primary_10_1016_j_jhep_2024_03_005 crossref_primary_10_3389_fmicb_2023_1169770 crossref_primary_10_1016_j_jcv_2024_105689 crossref_primary_10_1016_j_biopha_2023_116077 crossref_primary_10_4103_njcp_njcp_27_24 crossref_primary_10_1111_jcmm_17867 crossref_primary_10_1080_22221751_2024_2350167 crossref_primary_10_3390_v15091791 crossref_primary_10_1016_j_micpath_2025_107805 crossref_primary_10_1016_j_jhepr_2025_101471 crossref_primary_10_1111_liv_15417 crossref_primary_10_1016_j_gastre_2025_502337 crossref_primary_10_2147_IDR_S363609 crossref_primary_10_1111_trf_18238 crossref_primary_10_3390_v13091799 crossref_primary_10_3748_wjg_v29_i38_5395 crossref_primary_10_1016_j_jhep_2020_05_019 crossref_primary_10_1016_S1473_3099_22_00318_8 crossref_primary_10_1002_hep_32732 crossref_primary_10_3390_v16060817 crossref_primary_10_3390_microorganisms11071739 crossref_primary_10_1016_j_jceh_2024_101395 crossref_primary_10_30699_ijmm_18_1_1 crossref_primary_10_1080_23744235_2024_2434887 crossref_primary_10_7759_cureus_33660 crossref_primary_10_1016_j_jhep_2020_06_037 crossref_primary_10_1186_s12876_022_02317_7 crossref_primary_10_1177_00220345231186394 crossref_primary_10_2147_HMER_S352568 crossref_primary_10_1111_jvh_13889 crossref_primary_10_34084_bshr_1668347 crossref_primary_10_1080_13543784_2021_1977795 crossref_primary_10_1016_j_jhep_2023_02_041
ContentType	Journal Article
Copyright	The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Copyright_xml	– notice: The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. 2019 – notice: The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
DBID	TOX CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/infdis/jiz633
DatabaseName	Oxford Journals Open Access Collection Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1537-6613
EndPage	1687
ExternalDocumentID	31778167 10.1093/infdis/jiz633
Genre	Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article
GroupedDBID	--- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 29K 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWTL ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPTD ABQLI ABQNK ABTLG ABWST ABXVV ABZBJ ACGFO ACGFS ACGOD ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DIK DILTD DU5 D~K EBS ECGQY EE~ EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JLS JSG KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 M49 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NU- O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TOX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 ABDFA ABEJV ABGNP ABPQP ABVGC ADNBA AEMQT AFYAG AHMMS AJNCP ALXQX CGR CUY CVF ECM EIF JXSIZ NPM 7X8 AHGBF AJBYB
ID	FETCH-LOGICAL-c514t-7688fee26b7212b48f52e8491725c768a011403687c21110e19ac0e51d59b4723
IEDL.DBID	TOX
ISICitedReferencesCount	248
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000537439000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0022-1899 1537-6613
IngestDate	Sun Sep 28 02:29:00 EDT 2025 Thu Apr 03 06:53:43 EDT 2025 Wed Sep 11 04:40:20 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Keywords	epidemiology disease progression cirrhosis hepatitis delta virus hepatocellular carcinoma
Language	English
License	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c514t-7688fee26b7212b48f52e8491725c768a011403687c21110e19ac0e51d59b4723
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://dx.doi.org/10.1093/infdis/jiz633
PMID	31778167
PQID	2319492276
PQPubID	23479
PageCount	11
ParticipantIDs	proquest_miscellaneous_2319492276 pubmed_primary_31778167 oup_primary_10_1093_infdis_jiz633
PublicationCentury	2000
PublicationDate	2020-04-27
PublicationDateYYYYMMDD	2020-04-27
PublicationDate_xml	– month: 04 year: 2020 text: 2020-04-27 day: 27
PublicationDecade	2020
PublicationPlace	US
PublicationPlace_xml	– name: US – name: United States
PublicationTitle	The Journal of infectious diseases
PublicationTitleAlternate	J Infect Dis
PublicationYear	2020
Publisher	Oxford University Press
Publisher_xml	– name: Oxford University Press
References	31778169 - J Infect Dis. 2020 Apr 27;221(10):1573-1575
References_xml	– reference: 31778169 - J Infect Dis. 2020 Apr 27;221(10):1573-1575
SSID	ssj0004367
Score	2.6765304
SecondaryResourceType	review_article
Snippet	Abstract Background Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact... Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden...
SourceID	proquest pubmed oup
SourceType	Aggregation Database Index Database Publisher
StartPage	1677
SubjectTerms	Developing Countries Global Health Hepatitis D - epidemiology Hepatitis D - pathology Hepatitis D - virology Hepatitis Delta Virus Humans Prevalence Risk Factors
Title	Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection
URI	https://www.ncbi.nlm.nih.gov/pubmed/31778167 https://www.proquest.com/docview/2319492276
Volume	221
WOSCitedRecordID	wos000537439000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NT4MwFG90UePF74_5sdTE48igUNoejbrMRKcHNdwIlLJgls4MZqJ_va-UaeI87MIBCjSvr-nv1_ferwhdZm4mpZlpAP2pA_iWOIICa2U0Ny4gCam3Ll7v2XDIo0g8Nfsd5T8hfOH3wNJZUfbeiq_QN7KeHuXGoZ8fo98CSD9kc1lwDxhEI6a58PafKrYFMFkvKv3t5buzg7Ya4Iiv7EjvohWl99C6PUrycw9tPDRB8n2kb2HaGiCqRxjgHbay_tiINSV1iVEX39iwDNybjGwirO7iRGe4kQkd48dZBb6o8CTHA2WyrquixDdqXCX4tZjOSnzXZHHpA_TSv32-HjjNsQqOBHRUOUAweK4UCVNgfyQNeE6J4gHwNkIlPEwMR4KFjTMJ7NBzlScS6SrqZVSkASP-IWrpiVbHCGfMJz51VRByEZBEpkwpP8tNey5YStroAuwdv1vhjNgGvP3YmjC2JoQ289GIwbVNvCLRajIrY4CeIhCEsLCNjuww_XwKYA_jXshOlvjDKdokhiW7gUPYGWpV05k6R2vyAyw37aBVFnG4Dp8eOrVXfQNjmMbV
linkProvider	Oxford University Press
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimating+the+Global+Prevalence%2C+Disease+Progression%2C+and+Clinical+Outcome+of+Hepatitis+Delta+Virus+Infection&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Miao%2C+Zhijiang&rft.au=Zhang%2C+Shaoshi&rft.au=Ou%2C+Xumin&rft.au=Li%2C+Shan&rft.date=2020-04-27&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=221&rft.issue=10&rft.spage=1677&rft.epage=1687&rft_id=info:doi/10.1093%2Finfdis%2Fjiz633&rft.externalDocID=10.1093%2Finfdis%2Fjiz633
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon